Research graph
References from Chemoimmunotherapy‐associated CD20 ( MS4A1 ) resistance mutations in Waldenström macroglobulinemia: Epitope disruption independent of expression with implications for CD20‐directed cellular therapies. Local targets link to admitted publications; unresolved targets remain external evidence.
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment‐naïve patients
10.1053/j.seminhematol.2023.03.005 · 2023 · External reference
CD19‐directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience
10.1136/jitc-2021-004128 · 2022 · External reference
A phase 2 trial investigating epcoritamab in patients with previously treated Waldenstrom macroglobulinemia (WM)/lymphoplasmacytic lymphoma (WM‐NET3)
10.1182/blood-2024-206415 · 2024 · External reference
P1097: CD20 CAR‐T therapy with MB‐106 for BTK inhibitor‐refractory Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)—single institution study
10.1097/01.hs9.0000971284.68877.ca · 2023 · External reference
Plamotamab (XmAb®13676) for Ibrutinib‐ refractory CXCR4‐mutated extramedullary Waldenström macroglobulinemia
10.1080/10428194.2021.2005045 · 2022 · External reference
CD19‐targeting CAR T‐cell therapy in transformed Waldenström Macroglobulinemia/lymphoplasmacytic lymphoma: a Descar‐T and US collaborative study
10.1182/blood-2023-173988 · 2023 · External reference
A method for the elution of anti‐CD20 with an EDTA/glycine acid solution for accurate immunophenotyping of B lymphocytes sensitized with rituximab
10.1093/ajcp/aqab176 · 2022 · External reference
Double‐hit alterations of TP53 identify ultra high‐risk disease in previously treated, MYD88 mutated waldenstrom macroglobulinemia
10.1182/blood-2025-224 · 2025 · External reference
The mutational footprints of cancer therapies
10.1038/s41588-019-0525-5 · 2019 · External reference
Genetic and evolutionary patterns of treatment resistance in relapsed B‐cell lymphoma
10.1182/bloodadvances.2020001696 · 2020 · External reference
CD20 mutations involving the rituximab epitope are rare in diffuse large B‐cell lymphomas and are not a significant cause of R‐CHOP failure
10.3324/haematol.2008.001024 · 2009 · External reference
Identification of CD20 C‐terminal deletion mutations associated with loss of CD20 expression in non‐Hodgkin's lymphoma
10.1158/1078-0432.ccr-08-1403 · 2009 · External reference
The epitope recognized by rituximab
10.1182/blood-2006-04-014639 · 2006 · External reference
Combinability of epcoritamab CD20‐targeting T‐cell engager and CD20 antibody‐targeted therapies in B‐cell non‐Hodgkin lymphoma
10.1080/10428194.2025.2504719 · 2025 · External reference
Anti‐CD20/CD3 T cell‐dependent bispecific antibody for the treatment of B cell malignancies
2015 · External reference
CD20‐TCB with obinutuzumab pretreatment as next‐generation treatment of hematologic malignancies
10.1158/1078-0432.ccr-18-0455 · 2018 · External reference
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B‐cell lymphomas
10.1182/blood.2023022348 · 2024 · External reference
NCCN guidelines(R) insights: B‐cell lymphomas 3
2025 · External reference
Effective clearance of rituximab‐resistant tumor cells by breaking the mirror‐symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20
10.1038/s41598-023-45491-8 · 2023 · External reference
CD47 blockade by Hu5F9‐G4 and rituximab in non‐Hodgkin's lymphoma
10.1056/nejmoa1807315 · 2018 · External reference
